期刊
JOURNAL OF INFECTIOUS DISEASES
卷 223, 期 -, 页码 S296-S306出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa676
关键词
LACTIN-V; Lactobacillus crispatus CTV-05; bacterial vaginosis (BV); vaginal microbiota (VMB); live biotherapeutic product (LBP); women's health
资金
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases [HHSN2722013000141, HHSN27200007]
- Division of Microbiology and Infectious Diseases [HHSN272201 3000141]
Maintaining a dominant Lactobacillus species in the vaginal microbiota is crucial for preventing infections and supporting gynecologic health. Specific species like Lactobacillus crispatus are associated with preventing dysbiosis-related diseases. Therefore, replenishing the imbalanced microbiota with protective lactobacilli like CTV-05 may help in preventing recurrent BV.
A Lactobacillus-dominated vaginal microbiota (VMB) has been associated with health and considered an important host defense mechanism against urogenital infections. Conversely, depletion of lactobacilli and increased microbial diversity, amplifies the risk of adverse gynecologic and obstetric outcomes. A common clinical condition that exemplifies dysbiosis is bacterial vaginosis (BV). BV is currently treated with antibiotics, but frequently recurs, due in part to persistent dysbiosis and failure of lactobacilli to repopulate the vagina. New treatment options are needed to address By. The VMB is relatively simple and optimally dominated by one or several species of Lactobacillus. Lactobacillus crispatus is strongly associated with vaginal health and depleted in dysbiosis. Replenishing the dysbiotic VMB with protective L. crispatus CTV-05 is a promising approach to prevent recurrent infections and improve women's health. Here we discuss confirmation of this approach with the microbiome-based biologic drug, LACTIN-V (L. crispatus CTV-05), focusing on prevention of BV recurrence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据